BMY Q4 2023 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena

BMYBristol-Myers Squibb Company

$124B

Q4 2023 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$11.5B+0.6% YoY

Gross Profit

$6.5B56.6% margin

Operating Income

$2.0B17.0% margin

Net Income

$1.8B15.4% margin

EPS (Diluted)

$0.87

QoQ Revenue Growth

+4.7%

Cash Flow

Operating Cash Flow

$4.3B

Free Cash Flow

$3.9B

Stock-Based Comp.

$127M

Balance Sheet

Total Assets

$95.2B

Total Liabilities

$65.7B

Stockholders' Equity

$29.4B

Cash & Equivalents

$11.5B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11.5B	$11.4B	+0.6%
Gross Profit	$6.5B	$6.5B	+0.0%
Operating Income	$2.0B	$1.7B	+13.9%
Net Income	$1.8B	$2.0B	-12.9%

Revenue Segments

Eliquis

$2.9B26%

Opdivo

$2.4B22%

Revlimid

$1.4B13%

Orencia

$985M9%

Pomalyst/Imnovid

$890M8%

Yervoy

$566M5%

Sprycel

$526M5%

Reblozyl

$320M3%

Abraxane

$247M2%

Opdualag

$190M2%

Zeposia

$133M1%

Breyanzi

$101M1%

Abecma

$100M1%

Camzyos

$88M1%

Sotyktu

$63M1%

Geographic Segments

UNITED STATES

$8.0B70%

Rest Of World

$3.3B29%

Other Region

$184M2%